Medicinal chemistry of combretastatin A4: Present and future directions

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3033-3044

  Tron, Gian Cesare ^a   Pirali, Tracey ^a   Sorba, Giovanni ^a   Pagliai, Francesca ^a   Busacca, Sara ^a   Genazzani, Armando A ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; COMBRETASTATIN A4; PACLITAXEL; PODOPHYLLOTOXIN; STEGANACIN; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; MOLECULAR WEIGHT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SHORT SURVEY; SOLID TUMOR; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33744820579     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0512903     Document Type: Short Survey

References (102)

1. Burrows, F. J.; Thorpe, P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8996-9000.
2. Siemann, D. W.; Chaplin, D. J.; Horsman, M. R. Vascular targeted therapies for treatment of malignant disease Cancer 2004, 100, 2491-2499.
3. Neri, D.; Bicknell, R. Tumor vascular targeting. Nat. Rev. Cancer 2005, 5, 436-446.
4. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5, 423-435.
5. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25, 581-611.
6. Kanthou, C.; Tozer, G. M. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002, 99, 2060-2069.
7. Young, S. L.; Chaplin, D. J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin. Invest. Drugs 2004, 13, 1171-1182
8. Pinney, K. G.; Jelinek, C.; Evardsen, K.; Chaplin, D. J.; Pettit, G. R. The discovery and development of the combretastatins. In Anticancer Agents from Natural Products; Cragg, G. M., Kingston, D. G. I., Newman, D. J., Eds.; Brunner-Routledge Psychology Press. Taylor & Francis Group: Boca Raton, FL, 2005; pp 23-46.
9. Li, Q.; Sham, H. L. Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer. Expert Opin. Ther. Pat. 2002, 12, 1663-1701.
10. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989, 28, 6984-6991.
11. Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; et al. Antineoplastic agents. 84. Isolation and structure of combretastatin. Can. J. Chem. 1982, 60, 1374-1376.
12. Pettit, G. R.; Singh, S. B. Antineoplastic agents. 130. Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2. Can. J. Chem. 1987, 65, 2390-2396.
13. Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; et al. Antineoplastic agents. Part 123. Isolation, structure, and synthesis of combretastatin A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J. Nat. Prod. 1987, 50, 119-131.
14. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45, 209-211.
15. Pettit, G. R.; Temple, C., Jr.; Narayanan, V. L.; Varma, R.; Simpson, M. J.; et al. Antineoplastic agents. 322. synthesis of combretastatin A-4 prodrugs. Anti-Cancer Drug Des. 1995, 10, 299-309.
16. Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W. P.; Stratford, M.; et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002, 62, 3408-3416.
17. Stevenson, J. P.; Rosen, M.; Sun, W.; Gallagher, M.; Haller, D. G.; et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 2003, 21, 4428-4438.
18. Rustin, G. J.; Galbraith, S. M.; Anderson, H.; Stratford, M.; Folkes, L. K.; et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 2003, 21, 2815-2822.
19. Cooney, M. M.; Radivoyevitch, T.; Dowlati, A.; Overmoyer, B.; Levitan, N.; et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin. Cancer Res. 2004, 10, 96-100.
20. Galbraith, S. M.; Maxwell, R. J.; Lodge, M. A.; Tozer, G. M.; Wilson, J.; et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 2003, 21, 2831-2842.
21. Anderson, H. L.; Yap, J. T.; Miller, M. P.; Robbins, A.; Jones, T.; et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 2003, 21, 2823-2830.
22. Collins, J. M. Functional imaging in phase I studies: decorations or decision making? J. Clin. Oncol. 2003, 21, 2807-2809.
23. Nambu, H.; Nambu, R.; Melia, M.; Campochiaro, P. A. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 2003, 44, 3650-3655.
24. Escalona-Benz, E.; Jockovich, M. E.; Murray, T. G.; Hayden, B.; Hernandez, E.; et al. Combretastatin A4 prodrug in the treatment of a murine model of retinoblastoma. Invest. Ophthalmol. Visual Sci. 2005, 46, 8-11.
25. Griggs, J.; Skepper, J. N.; Smith, G. A.; Brindle, K. M.; Metcalfe, J. C.; et al. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am. J. Pathol. 2002, 160, 1097-1103.
26. Gaukroger, K.; Hadfield, J. A.; Hepworth, L. A.; Lawrence, N. J.; McGown, A. T. Novel syntheses of cis and trans isomers of combretastatin A-4. J. Org. Chem. 2001, 66, 8135-8138.
27. Solladié, G.; Pasturel-Jacopé, Y.; Maignan, J. A re-investigation of resveratrol synthesis by Perkin reaction. Application to the synthesis of aryl cinnamic acids. Tetrahedron 2003, 59, 3315-3321.
28. Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with mitotic spindle. Med. Res. Rev. 1998, 18, 259-296.
29. Cushman, M.; Nagarathnam, D.; Gopal, D.; He, H. M.; Lin, C. M.; et al. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5- trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J. Med. Chem. 1992, 35, 2293-2306.
30. Gaukroger, K.; Hadfield, J. A.; Lawrence, N. J.; Nolan, S.; McGown, A. T. Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit? Org. Biomol. Chem. 2003, 1, 3033-3037.
31. Maya, A. B.; Perez-Melero, C.; Mateo, C.; Alonso, D.; Fernandez, J. L.; et al. Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety. J. Med. Chem. 2005, 48, 556-568.
32. Pettit, G. R.; Minardi, M. D.; Rosenberg, H. J.; Hamel, E.; Bibby, M. C.; et al. Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1). J. Nat. Prod. 2005, 68, 1450-1458.
33. Pettit, G. R.; Anderson, C. R.; Herald, D. L.; Jung, M. K.; Lee, D. J.; et al. Antineoplastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3,4-methylenedioxy-5,4′-dimethoxy-3′-amino-Z- stilbene and derived amino acid amides. J. Med. Chem. 2003, 46, 525-531.
34. Medarde, M.; Ramos, A. C.; Caballero, E.; Pelaez, R.; Lopez, J. L.; et al. Synthesis and antineoplastic activity of combretastatin analogues: heterocombretastatins. Eur. J. Med. Chem. 1998, 33, 71-77.
35. Maya, A. B.; del Rey, B.; Lamamie de Clairac, R. P.; Caballero, E.; Barasoain, I.; et al. Design, synthesis and cytotoxic activities of naphthyl analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. 2000, 10, 2549-2551.
36. Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin, C. M.; et al. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J. Med. Chem. 1991, 34, 2579-2588.
37. Lawrence, N. J.; Hepworth, L. A.; Rennison, D.; McGown, A. T.; Hadfield, J. A. Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4. J. Fluorine Chem. 2003, 123, 101-108.
38. Kirwan, I. G.; Loadman, P. M.; Swaine, D. J.; Anthoney, D. A.; Pettit, G. R.; et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and Al phosphate. Clin. Cancer Res. 2004, 10, 1446-1453.
39. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Hamel, E.; Schmidt, J. M.; et al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-4. J. Med. Chem. 2005, 48, 4087-4099.
40. Pinney, K. G.; Mejia, M. P.; Villalobos, V. M.; Rosenquist, B. E.; Pettit, G. R.; et al. Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorg. Med. Chem. 2000, 8, 2417-2425.
41. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; et al. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J. Med. Chem. 1998, 41, 3022-3032.
42. Kong, Y.; Grembecka, J.; Edler, M. C.; Hamel, E.; Mooberry, S. L.; et al. Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem. Biol. 2005, 12, 1007-1014.
43. Kolb, H. C.; Sharpless, K. B. The growing impact of click chemistry on drug discovery. Drug Discovery Today 2003, 8, 1128-1137.
44. Lawrence, N. J.; Rennison, D.; Woo, M.; McGown, A. T.; Hadfield, J. A. Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg. Med. Chem. Lett. 2001, 11, 51-54.
45. Holwell, S. E.; Cooper, P. A.; Grosios, K.; Lippert, J. W., 3rd; Pettit, G. R.; et al. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res. 2002, 22, 707-711.
46. Sheng, Y.; Hua, J.; Pinney, K. G.; Garner, C. M.; Kane, R. R.; et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int. J. Cancer 2004, 111, 604-610.
47. Monk, K. A.; Siles, R.; Hadimani, M. B.; Mugabe, B. E.; Ackley, J. F.; et al. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents. Bioorg. Med. Chem. 2006, 14, 3231-3244.
48. Hatanaka, T.; Fujita, K.; Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; et al. Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg. Med. Chem. Lett. 1998, 8, 3371-3374.
49. Perez-Melero, C.; Maya, A. B.; del Rey, B.; Pelaez, R.; Caballero, E.; et al. A new family of quinoline and quinoxaline analogues of combretastatins. Bioorg. Med. Chem. Lett. 2004, 14, 3771-3774.
50. Medarde, M.; Maya, A. B.; Perez-Melero, C. Naphthalene combretastatin analogues: synthesis, cytotoxicity and antitubulin activity. J. Enzyme Inhib. Med. Chem. 2004, 19, 521-540.
51. Wardman, P.; Folkes, L. K.; Burkitt, M. J.; Stratford, M. R. L. Oxidative metabolism on combreatastatin A-1 but not A-4 as the potential to generate high hydroxyl free radicals via a reactive quinine intermediate. Presented at The Tumor Microenviroment: Hypoxia, Angiogenesis and Vasculature, 9th International Workshop, Oxford. U.K., August 20-23, 2005.
52. Metzler, M.; Neumann, H. G. Epoxidation of the stilbene double bond, a major pathway in aminostilbene metabolism. Xenobiotica 1977, 7, 117-132.
53. Getahun, Z.; Jurd, L.; Chu, P. S.; Lin, C. M.; Hamel, E. Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions. J. Med. Chem. 1992, 35, 1058-1067.
54. Pettit, G. R.; Toki, B.; Herald, D. L.; Verdier-Pinard, P.; Boyd, M. R.; et al. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J. Med. Chem. 1998, 41, 1688-1695.
55. Liou, J. P.; Chang, Y. L.; Kuo, F. M.; Chang, C. W.; Tseng, H. Y.; et al. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J. Med. Chem. 2004, 47, 4247-4257.
56. Liou, J. P.; Chang, J. Y.; Chang, C. W.; Chang, C. Y.; Mahindroo, N.; et al. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. J. Med. Chem. 2004, 47, 2897-2905.
57. Liou, J. P.; Chang, C. W.; Song, J. S.; Yang, Y. N.; Yeh, C. F.; et al. Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J. Med. Chem. 2002, 45, 2556-2562.
58. Kaffy, J.; Pontikis, R.; Florent, J. C.; Monneret, C. Synthesis and biological evaluation of vinylogous combretastatin A-4 derivatives. Org. Biomol. Chem. 2005, 3, 2657-2660.
59. Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.; Lawrence, N. J.; et al. Potent antimitotic and cell growth inhinitory properties of substituted chalcones. Bioorg. Med. Chem. 1998, 8, 1051-1056.
60. Larsen, M.; Kromann, H.; Kharazmi, A.; Nielsen, S. F. Conformationally restricted anti-plasmodial chalcones. Bioorg. Med. Chem. Lett. 2005, 15, 4858-4861.
61. Flynn, B. L.; Hamel, E.; Jung, M. K. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J. Med. Chem. 2002, 45, 2670-2673.
62. Lawrence, N. J.; McGown, A. T. The chemistry and biology of antimitotic chalcones and related enone systems. Curr. Pharm. Des. 2005, 11, 1679-1693.
63. Romagnoli, R.; Baraldi, P. G.; Jung, M. K.; Iaconinoto, M. A.; Carrion, M. D.; et al. Synthesis and preliminary biological evaluation of new anti-tubulin agents containing different benzoheterocycles. Bioorg. Med. Chem. Lett. 2005, 15, 4048-4052.
64. Shirai, R.; Tokuda, K.; Koiso, Y.; Iwasaki, S. Synthesis and antitubulin activity of aza-combretastatins. Bioorg. Med. Chem. Lett. 1994, 4, 699-704.
65. Gwaltney, S. L., 2nd; Imade, H. M.; Barr, K. J.; Li, Q.; Gehrke, L.; et al. Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg. Med. Chem. Lett. 2001, 11, 871-874.
66. Borrel, C.; Thoret, S.; Cachet, X.; Guenard, D.; Tillequin, F.; et al. New antitubulin derivatives in the combretastatin A4 series: synthesis and biological evaluation. Bioorg. Med. Chem. 2005, 13, 3853-3864.
67. Hadfield, J. A.; Gaukroger, K.; Hirst, N.; Weston, A. P.; Lawrence, N. J.; et al. Synthesis and evaluation of double bond substituted combretastatins. Eur. J. Med. Chem. 2005, 40, 529-541.
68. Shirai, R.; Okabe, T.; Iwasaki, S. Synthesis of conformationary restricted combretastatins. Heterocycles 1997, 46, 145-148.
69. Pettit, G. R.; Toki, B. E.; Herald, D. L.; Boyd, M. R.; Hamel, E.; et al. Antineoplastic agents. 410. Asymmetric hydroxylation of transcombretastatin A-4. J. Med. Chem. 1999, 42, 1459-1465.
70. Giannini, G.; Marzi, M.; Alloatti, D.; Tinti, M. O.; Riccioni, T.; et al. GB 2403949, 2005.
71. Ohsumi, K.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; et al. Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg. Med. Chem. Lett. 1998, 8, 3153-3158.
72. ter Haar, E.; Rosenkranz, H. S.; Hamel, E.; Day, B. W. Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents. Bioorg. Med. Chem. 1996, 4, 1659-1671.
73. Mateo, C.; Perez-Melero, C.; Pelaez, R.; Medarde, M. Stilbenophane analogues of deoxycombretastatin A-4. J. Org. Chem. 2005, 70, 6544-6547.
74. Nam, N. H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem. 2003, 10, 1697-1722.
75. Tron, G. C.; Pagliai, F.; Del Grosso, E.; Genazzani, A. A.; Sorba, G. Synthesis and cytotoxic evaluation of combretafurazans. J. Med. Chem. 2005, 48, 3260-3268.
76. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem. 2002, 45, 1697-1711.
77. Bailly, C.; Bal, C.; Barbier, P.; Combes, S.; Finet, J. P.; et al. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. J. Med. Chem. 2003, 46, 5437-5444.
78. Pati, H. N.; Wicks, M.; Holt, H. L., Jr.; LeBlanc, R.; Weisbruch, P.; et al. Synthesis and biological evaluation of cis-combretastatin analogs and their novel 1,2,3-triazole derivatives. Heterocycl. Commun. 2005, 11, 117-120.
79. Kim, Y.; Nam, N. H.; You, Y. J.; Ahn, B. Z. Synthesis and cytotoxicity of 3,4-diaryl-2(5H)-furanones. Bioorg. Med. Chem. Lett. 2002, 12, 719-722.
80. Nam, N. H.; Kim, Y.; You, Y. J.; Hong, D. H.; Kim, H. M.; et al. Combretoxazolones: synthesis, cytotoxicity and antitumor activity. Bioorg. Med. Chem. Lett. 2001, 11, 3073-3076.
81. Nam, N. H.; Kim, Y.; You, Y. J.; Hong, D. H.; Kim, H. M.; et al. Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues. Bioorg. Med. Chem. Lett. 2002, 12, 1955-1958.
82. Simoni, D.; Grisolia, G.; Giannini, G.; Roberti, M.; Rondanin, R.; et al. Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J. Med. Chem. 2005, 48, 723-736.
83. Flynn, B. L.; Flynn, G. P.; Hamel, E.; Jung, M. K. The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. 2001, 11, 2341-2343.
84. Sharma, V. M.; Adi Seshu, K. V.; Krishna, C. V.; Prasanna, P.; Sekhar, V. C.; et al. Novel 5,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues as cytotoxic agents. Bioorg. Med. Chem. Lett. 2003, 13, 1679-1682.
85. Jonnalagadda, S. S.; ter Haar, E.; Hamel, E.; Lin, C. M.; Magarian, R. A.; et al. Synthesis and biological evaluation of 1,1-dichloro-2,3- diarylcyclopropanes as antitubulin and anti-breast cancer agents. Bioorg. Med. Chem. 1997, 5, 715-722.
86. Sun, L.; Vasilevich, N. I.; Fuselier, J. A.; Hocart, S. J.; Coy, D. H. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg. Med. Chem. Lett. 2004, 14, 2041-2046.
87. LeBlanc, R.; Dickson, J.; Brown, T.; Stewart, M.; Pati, H. N.; et al. Synthesis and cytotoxicity of epoxide and pyrazole analogs of the combretastatins. Bioorg. Med. Chem. 2005, 13, 6025-6034.
88. Bhat, B. A.; Dhar, K. L.; Puri, S. C.; Saxena, A. K.; Shanmugavel, M.; et al. Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Bioorg. Med. Chem. Lett. 2005, 15, 3177-3180.
89. Lawrence, N. J.; Rennison, D.; McGown, A. T.; Hadfield, J. A. The total synthesis of an aurone isolated from Uvaria hamiltonii: aurones and flavones as anticancer agents. Bioorg. Med. Chem. Lett. 2003, 13, 3759-3763.
90. Li, P. K.; Xiao, Z.; Hu, Z.; Pandit, B.; Sun, Y.; et al. Conformationally restricted analogs of combretastatin A-4 derived from SU5416. Bioorg. Med. Chem. Lett. 2005, 15, 5382-5385.
91. Rizzi, E.; Dallavalle, S.; Merlini, L.; Beretta, G. L.; Pratesi, G.; et al. A new synthesis of isoaurones: cytotoxic activity of compounds related to the alleged structure of isoaurostatin. Bioorg. Med. Chem. Lett. 2005, 15, 4313-4316.
92. Lawrence, N. J.; Ghani, F. A.; Hepworth, L. A.; Hadfield, J. A.; McGown, A. T.; et al. The synthesis of (E) and (Z)-combretastatin A-4 and a phenanthrene from Combretum caffrum. Synthesis 1999, 1656-1660.
93. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem. Biophys. 2003, 38, 1-22.
94. Prinz, H.; Ishii, Y.; Hirano, T.; Stoiber, T.; Camacho Gomez, J. A.; et al. Novel benzylidene-9-(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization. J. Med. Chem. 2003, 46, 3382-3394.
95. Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Petit, G. R.; Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997, 57, 1829-1834.
96. Wehbe, H.; Kearney, C. M.; Pinney, K. G. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Anticancer Res. 2005, 25, 3865-3870.
97. Islam, M. N.; Iskander, M. N. Microtubulin binding sites as target for developing anticancer agents. Mini-Rev. Med. Chem. 2004, 4, 1077-1104.
98. Vincent, L.; Kermani, P.; Young, L. M.; Cheng, J.; Zhang, F.; et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signalling. J. Clin. Invest. 2005, 115, 2992-3006
99. Coggiola, B.; Pagliai, F.; Allegrone, G.; Genazzani, A. A.; Tron, G. C. Synthesis and biological activity of mustard derivatives of combretastatins. Bioorg. Med. Chem. Lett. 2005, 15, 3551-3554.
100. Andres, C. J.; Bernardo, J. E.; Yan, Q.; Hastie, S. B.; Macdonald, T. L. "Combretatropones", hybrids of combretastatin and colchicine, synthesis and biochemical evaluation. Bioarg. Med. Chem. Lett. 1993, 3, 565-570.
101. Janik, M. E.; Bane, S. L. Synthesis and antimicrotubule activity of combretatropone derivatives. Bioorg. Med. Chem. 2002, 10, 1895-1903.
102. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436, 568-572.